Please use this identifier to cite or link to this item:
metadata.artigo.dc.title: Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment
metadata.artigo.dc.creator: Biembengut, Ísis Venturi
Souza, Tatiana de Arruda Campos Brasil de
metadata.artigo.dc.subject: COVID-19
In silico approach
Proteínas de Transporte
metadata.artigo.dc.publisher: Fundação Oswaldo Cruz. Instituto Oswaldo Cruz 17-Apr-2020
metadata.artigo.dc.identifier.citation: BIEMBENGUT, I. V.; SOUZA, T. de A. C. B. de. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, p. 1-10, 17 Apr. 2020.
metadata.artigo.dc.description.abstract: SARS-CoV-2 infection depends on viral polyprotein processing, an event catalyzed by the main proteinase Mpro. The solution of the SARS-CoV-2 Mpro tridimensional structure in the last month allowed the investigation of potential inhibitors of viral replication. As objective, this work aims to provide first evidences of the applicability of commercial y approved drugs to treat COVID-19. As methods used in this research: We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Thereby we have as findings that, The higher scores interactions include antiviral components and drugs classified as coagulation modifiers, ACE and dipeptidyl peptidase 4 inhibitors, antimigraine agents, antihistamine. And finally as main conclusions: Our result evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV main protease Mpro and human coagulation factors thrombin and Factor Xa.
metadata.artigo.dc.language: pt_BR
Appears in Collections:DSA - Artigos publicados em periódicos

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.